Breast Care

Papers
(The TQCC of Breast Care is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer88
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 202150
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 202246
St. Gallen/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer – A Brief Summary of the Consensus Discussion19
Breast Disorders in Adolescence: A Review of the Literature19
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 202118
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 202316
Diffusion-Weighted Imaging of Different Breast Cancer Molecular Subtypes: A Systematic Review and Meta-Analysis16
HER2-Low Breast Cancer: Where Are We?16
Risk Factors for Idiopathic Granulomatous Mastitis Recurrence after Patient-Tailored Treatment: Do We Need an Escalating Treatment Algorithm?15
Resistance Exercise for Breast Cancer Patients? Evidence from the Last Decade15
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 202314
Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer13
Low-Dose Methotrexate Use in Idiopathic Granulomatous Mastitis: An Alternative Treatment Method13
CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis12
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 202212
False Negativity of Targeted Axillary Dissection in Breast Cancer11
Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping11
Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?10
Impact of Oncoplastic Breast Surgery on Rate of Complications, Time to Adjuvant Treatment, and Risk of Recurrence10
Effectiveness of Peer Support on Quality of Life and Anxiety in Breast Cancer Patients: A Systematic Review and Meta-Analysis9
Malignancy Rate and Malignancy Risk Assessment in Different Lesions of Uncertain Malignant Potential in the Breast (B3 Lesions): An Analysis of 192 Cases from a Single Institution8
Factors Indicating Surgical Excision in Classical Type of Lobular Neoplasia of the Breast7
De-Escalating Axillary Surgery in Node-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy7
Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Canc7
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer7
Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors7
Targeted Axillary Dissection after Chemotherapy: Feasibility Study with Clip and Carbon Dye Tattoo – Neotarget Trial7
Quality Analysis of YouTube Videos Presenting Shoulder Exercises after Breast Cancer Surgery7
Ten-Year Survival of Breast Cancer in Iran: A National Study (Retrospective Cohort Study)7
ABC6 Consensus: Assessment by a Group of German Experts7
Current Understanding and Management of Plasma Cell Mastitis: Can We Benefit from What We Know?7
From <b><i>BRCA1</i></b> to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes6
Adherence to Newly Implemented Tamoxifen Therapy for Breast Cancer Patients in Rural Western Ethiopia6
Patient-Reported Outcomes in Free-Flap Breast Reconstructive Surgery over Time (PRO-BREST)6
Long-Term Results of the TARGIT-A Trial: More Questions than Answers6
Multistage Latissimus Dorsi Flap with Implant for Complex Post-Mastectomy Reconstruction: An Old but Still Current Technique5
Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving5
Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment5
Augmented Reality in Breast Surgery Education5
Management of Idiopathic Granulomatous Mastitis: A Single Institution Experience5
Second-Degree Type 2 Atrioventricular Block Requiring Permanent Cardiac Pacing in Patients on CDK4/6 Inhibitors: Report of Two Cases5
Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet5
Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review5
Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer4
Treatments for Periductal Mastitis: Systematic Review and Meta-Analysis4
Prevalence of Pathogenic Germline Variants in Women with Non-Familial Unilateral Triple-Negative Breast Cancer4
Long-Term Outcome Analysis and Technical Refinements after Autologous Breast Reconstruction with PAP Flap: What We Have Learnt4
The Role of Social Media and Breast Cancer: How Does It Impact Patients?4
Quality and Quantity: How to Organize a Countrywide Genetic Counseling and Testing4
Expert Discussion: Highlights from ABC6: Bridging the Gap and Insights in This First Virtual ABC Conference and from 10 Years ABC Consensus4
Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer4
Assessment of MRI-Detected Breast Lesions: A Benign Correlate on Second-Look Ultrasound Can Safely Exclude Malignancy4
Prognostic Impact of Immunoglobulin Kappa C in Breast Cancer Patients Treated with Adjuvant Chemotherapy4
Awareness and Availability of Routine Germline <b><i>BRCA1/2</i></b> Mutation Testing in Patients with Advanced Breast Cancer in Germany4
Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period4
App-Based Lifestyle Coaching (PINK!) Accompanying Breast Cancer Patients and Survivors to Reduce Psychological Distress and Fatigue and Improve Physical Activity: A Feasibility Pilot Study4
Survey on Physicians’ Knowledge and Training Needs in Genetic Counseling in Germany4
The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer3
Influence of Breast Reduction Surgery on Long-Term Breast Cancer Risk in Austria3
Innovative Standards in Oncoplastic Breast Conserving Surgery: From Radical Mastectomy to Extreme Oncoplasty3
Breast Adjuvant Radiotherapy Amid the COVID-19 Crisis in a Hub Cancer Center, Lombardy, Italy3
First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center3
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)3
Evaluation of the Effect of Axillary Radiotherapy Dose and the Development of Lymphedema in Breast Cancer Patients3
Luminal Metastatic Breast Cancer: Current Concepts and Future Approaches3
PITX2 DNA-Methylation: Predictive versus Prognostic Value for Anthracycline-Based Chemotherapy in Triple-Negative Breast Cancer Patients3
Clinical Importance of PGRMC1 in Hormone Responsive Breast Cancer3
What Has Changed in Patients Aged 65 and over Diagnosed with Breast Cancer during the COVID-19 Pandemic: A Single-Center Experience3
Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown, BRCA1/2 Muta3
Innovative Standards in Surgery of the Breast after Neoadjuvant Systemic Therapy3
Invasive Lobular Carcinoma Has Worse Outcome Compared with Invasive Ductal Carcinoma in Stage IV Breast Cancer with Bone-Only Metastasis3
0.038031816482544